Trial Profile
A multicenter, randomized, double-blind, 'factorial' design study to evaluate the lipid-altering efficacy and safety of coadministered MK0524B tablets [niacin/laropiprant/simvastatin] in patients with primary hypercholesterolemia or mixed hyperlipidemia [type V hyperlipoproteinaemia]
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 06 May 2022
Price :
$35
*
At a glance
- Drugs Laropiprant/niacin/simvastatin (Primary) ; Niacin/laropiprant; Simvastatin
- Indications Hypercholesterolaemia; Hyperlipoproteinaemia type V; Lipid metabolism disorders
- Focus Registrational; Therapeutic Use
- Acronyms Factorial
- Sponsors Merck Sharp & Dohme
- 13 Jun 2019 Trial has been completed in UK.
- 18 May 2008 Results reported at WCC 2008
- 11 Mar 2008 Status changed from in progress to completed according to ClinicalTrials.gov.